A CCK receptor antagonist (Kis = 9.1 and 0.33 μM for CCK-8 binding to central and peripheral CCK receptors, respectively); inhibits CCK-8-induced release of acetylcholine from isolated guinea pig gallbladders (IC50 = 10 nM); reduces the invasion of PANC-1 and MiaPaCa-2 human pancreatic cancer cells at 50 μM; reduces DNA synthesis in PC-TI and PC-YY human pancreatic cancer cells (IC50s = 160 and 74 μM, respectively); reduces tumor growth rate in PC-TI and PC-YY mouse xenograft models at 250 mg/kg; toxic to mice (LD50s = 440-500 mg/kg); reduces serum concentrations of CCK, amylase, and lipase as well as tissue hemorrhaging and acinar cell necrosis in a rat model of acute pancreatitis at 50 mg/kg